Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells
Kidney International · 2026-01 · 109 (1) · 89-100
DOI: 10.1016/j.kint.2025.09.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026-01. Verfasst von Burcin Altun und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, B-Lymphocytes, Autoantibodies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Irving Medical Center, Columbia University, Boston University.
Abstract (Originalsprache)
INTRODUCTION: Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, driven by autoantibodies that target PLA2R on kidney podocytes. Antibody-based therapy with rituximab induces broad B-cell depletion but is associated with risks of serious infection and reduced efficacy in patients with high proteinuria. Here, we determined the feasibility of developing chimeric autoantibody receptor T-cell (CAART) therapy for PLA2R-specific B-cell depletion in PLA2R MN. METHODS: PLA2R-CAART was produced by T-cell lentiviral transduction. In vitro cytotoxicity and specificity were evaluated against B-cell lines targeting PLA2R immunodominant epitopes and primary PLA2R MN B cells. Adsorption of PLA2R MN IgG was evaluated to determine the extent of pathogenic autoantibody targeting by candidate PLA2R-CAART designs. Specific cytotoxicity, engraftment capability, and off-target toxicity were evaluated in a xenografted anti-PLA2R Nalm-6 preclinical mouse model, with additional toxicology screening by human membrane proteome arrays. RESULTS: We engineered CAARTs targeting key PLA2R epitopes to selectively deplete autoreactive B cells. C17- and C178-CAART (encompassing CysR, CTLD1, and CTLD7, with/without CTLD8 domains) were successfully expressed on primary T cells and demonstrated specific in vitro cytotoxicity against anti-PLA2R B-cell lines targeting CysR, CTLD1, and CTLD7 epitopes. In co-incubation assays with primary B cells or plasma from patients with MN, C17- and C178-CAART significantly reduced anti-PLA2R B cells and adsorbed 69-97% of plasma anti-PLA2R antibody reactivity. In vivo, C17- and C178-CAART treatment in the Nalm-6 xenograft model resulted in significant reduction in target cell outgrowth with C17-CAART showing slight but consistently increased cytotoxic activity. Specificity testing through comprehensive in vivo pathologic analysis and a high-throughput membrane proteome array analysis showed no significant off-target binding for either C17- or C178-CAART. CONCLUSIONS: Our findings establish preclinical proof-of-concept for the therapeutic potential of antigen-specific B-cell depletion by PLA2R-CAART. Additional studies are required to determine clinical feasibility of PLA2R-CAART for PLA2R MN therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Dermatology, Columbia University, New York, New York, USA.
- Department of Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Cabaletta Bio, Philadelphia, Pennsylvania, USA.
- Department of Dermatology, Columbia University, New York, New York, USA. Electronic address: asp2261@cumc.columbia.edu.
Förderung
- NCI NIH HHS
- Irving Medical Center, Columbia University
- Boston University
- University of Pennsylvania
- National Cancer Institute
- Abramson Cancer Center
- Cabaletta Bio
- National Institutes of Health
Zitieren
APA
Altun, B., Zhao, G., Wang, B., Mao, X., Manfredo-Vieira, S., Willis, E., Radaelli, E., Goodman, E. E., Boesteanu, A. C., Gill, S. I., Patel, D. R., Wong, S., Cottman-Thomas, E., Hogan, J. J., & Payne, A. S. (2026). Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells. Kidney International, 109(1), 89-100. https://doi.org/10.1016/j.kint.2025.09.028
Vancouver
Altun B, Zhao G, Wang B, Mao X, Manfredo-Vieira S, Willis E, et al. Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells. Kidney International. 2026;109(1):89-100. doi:10.1016/j.kint.2025.09.028
BibTeX
@article{Altun2026,
author = {Altun, Burcin and Zhao, Gexin and Wang, Baomei and Mao, Xuming and Manfredo-Vieira, Silvio and Willis, Elinor and Radaelli, Enrico and Goodman, Emma E and Boesteanu, Alina C and Gill, Saar I and Patel, Darshil R and Wong, Steven and Cottman-Thomas, Ebony and Hogan, Jonathan J and Payne, Aimee S},
title = {Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells},
journal = {Kidney International},
year = {2026},
volume = {109},
number = {1},
pages = {89--100},
doi = {10.1016/j.kint.2025.09.028}
}
EUVIMED